+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Aortic Calcification Produced by Vitamin D 3 plus Nicotine

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Calcification of the elastic arteries of the young rat by treatment with vitamin D and nicotine (VDN) has been proposed as an animal model of arterial calcification associated with age and age-related vascular pathology in man. The calcium-binding protein, S-100, which is found in human atherosclerotic lesions was associated with medial calcification of the aorta in VDN rats, especially in cases of severe calcification. Calcification (total calcium content: 366 ± 87, n = 12 in VDN vs. 24 ± 2 µmol g<sup>–1</sup> aortic dry weight in controls, n = 13) involved elastocalcinosis leading to elastolysis as revealed by a fall in the amount of desmosine and isodesmosine in the aortic wall (266 ± 17 and 254 ± 15 in VDN vs. 655 ± 56 and 588 ± 30 µg g<sup>–1</sup> aortic dry weight in controls). The decrease in elastin was associated with an increase in the stiffness of the aortic wall (elastic modulus: 15.1 ± 1.8 in VDN vs. 6.7 ± 0.5 10<sup>6</sup> dyn cm<sup>–2</sup>in controls), an increase in end-systolic stress (central systolic aortic pressure: 152 ± 6 in VDN vs. 136 ± 2 mm Hg in controls) (at a normotensive mean pressure level) and left ventricular hypertrophy (heart weight/body weight 2.51 ± 0.10 in VDN vs. 2.24 ± 0.07 g kg<sup>–1</sup> in controls). In conclusion, the mechanisms and consequences of aortic calcification in VDN show several similarities with calcification occurring in human athero- and arteriosclerosis.

          Related collections

          Author and article information

          J Vasc Res
          Journal of Vascular Research
          S. Karger AG
          24 September 2008
          : 34
          : 5
          : 386-398
          aLaboratoire de Pharmacologie Cardio-vasculaire, Faculté de Pharmacie de l’Université Henri-Poincaré, Nancy I, France; bSurgical Professorial Unit, Level 17, O’Brien Building, St. Vincent’s Hospital, Darlinghurst, Australia
          159247 J Vasc Res 1997;34:386–398
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 13
          Research Paper


          Comment on this article